Full Press Release Details
Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM®.
BIIB
Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM®
Key Takeaway: Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM®
Price reaction · baseline $219.6 (2022-01-26 close) · hit after-hours · 2 other BIIB headline(s) in the window, move may be shared
day 0 close
-0.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis